IPA publishes its scientific paper concerning TATX-03 on bioRxiv
IPA to host an earnings conference call via webcast on July 28, 2021, after the close of market
The collaboration provides greater access to solutions that empower scientists to pursue life-changing medicines.
IPA announces optimization results of TATX-03 cocktail components designed to improve clinical suitability of their PolyTope therapy
TATX-21, a novel potential first-in-class antibody for Atherosclerosis Cardiovascular Disease (ACVD).
Since 2019, Dr. Ilse Roodink has served as Chairwoman of Talem Therapeutics’ Scientific Advisory Committee and has been instrumental in leading IPA’s SARS-CoV-2 Polytope™ Cocktail program